Ask AI
ProCE Banner Activity

Advancing Pharmacist Excellence in RRMM: Optimizing Bispecific Antibody Selection, Safety, and Patient Care

Slideset

Downloadable slides on the efficacy and safety of bispecific antibodies currently approved to manage relapsed/refractory multiple myeloma based on clinical trial data and guideline recommendations.

Released: May 20, 2026

Share

Provided by

Provided by ProCE, LLC.

ProCE Banner

Supporters

Supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc.

Regeneron Pharmaceuticals, Inc

Target Audience

This activity has been designed to meet the educational needs of pharmacists and other healthcare professionals caring for patients with multiple myeloma.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Recognize key toxicities such as cytokine release syndrome, immune effector cell–associated neurotoxicity syndrome, cytopenias, infections, and agent-specific effects, using current guideline-based tools and protocols

  • Interpret clinical trial data and real-world evidence to differentiate bispecific antibodies by targets, dosing strategies, safety profiles, and administration nuances, facilitating optimal agent selection and sequencing in relapsed/refractory multiple myeloma

  • Develop competence in multidisciplinary care coordination, including managing inpatient ramp-up and outpatient maintenance workflows, emergency department collaboration for AE emergencies, and adherence to mandated REMS requirements

  • Build skills to effectively counsel patients and caregivers on therapy expectations, AE recognition and reporting, infection prevention, adherence, and navigate equitable access challenges, especially for underserved populations